The Readout Loud
En podkast av STAT - Torsdager
350 Episoder
-
346: Zealand's obesity strategy and Immunovant's curious development plan
Publisert: 20.3.2025 -
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Publisert: 13.3.2025 -
344: Trump's FDA commissioner nominee takes the hot seat
Publisert: 6.3.2025 -
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Publisert: 27.2.2025 -
342: FDA cuts, zombie biotechs, and too much weight loss?
Publisert: 20.2.2025 -
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Publisert: 13.2.2025 -
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Publisert: 6.2.2025 -
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Publisert: 30.1.2025 -
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Publisert: 23.1.2025 -
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Publisert: 15.1.2025 -
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Publisert: 9.1.2025 -
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Publisert: 19.12.2024 -
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Publisert: 12.12.2024 -
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Publisert: 5.12.2024 -
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Publisert: 21.11.2024 -
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Publisert: 14.11.2024 -
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Publisert: 7.11.2024 -
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Publisert: 31.10.2024 -
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Publisert: 24.10.2024 -
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Publisert: 17.10.2024
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
